1-5 of 5
Richard Larson, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

David A. Rizzieri, MD, Jeffrey L Johnson, John C. Byrd, MD, Gerard Lozanski, MD, Bayard L. Powell, MD, Thomas C. Shea, MD, Sreenivasa Nattom, Eva Hoke, Bruce D. Cheson, MD, Richard Larson, M.D.
Journal: Blood
Blood (2010) 116 (21): 858.
https://doi.org/10.1182/blood.V116.21.858.858
Published: 2010
Journal Articles

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Xiaopan Yao, PhD, MS, Elisabeth Paietta, PhD, Rhett Ketterling, Witold Rybka, MD, Mark R. Litzow, MD, Jacob M. Rowe, Richard Larson, M.D., Martin S. Tallman, MD
Journal: Blood
Blood (2010) 116 (21): 3315.
https://doi.org/10.1182/blood.V116.21.3315.3315
Published: 2010
Journal Articles

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Eyal C Attar, M.D., Kathleen A. Donohue, M.A., Philip C. Amrein, MD, Martha Wadleigh, MD, Daniel J DeAngelo, MD, PhD, Jonathan E Kolitz, MD, Bayard L. Powell, MD, Peter M Voorhees, M.D., Eunice S. Wang, MD, William Blum, MD, Allison Booth, Richard M Stone, M.D., Barry K Moser, Ph.D., Richard Larson, M.D.
Journal: Blood
Blood (2010) 116 (21): 331.
https://doi.org/10.1182/blood.V116.21.331.331
Published: 2010
Journal Articles

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Mark C Lanasa, MD, PhD, Leslie Andritsos, MD, Jennifer R Brown, MD, PhD, Janice Gabrilove, M.D., Federico Caligaris-Cappio, M.D., Richard Larson, M.D., Thomas J. Kipps, MD, PhD, Veronique Leblond, M.D., Donald Milligan, MD, FRCP, FRCPath, Ann Janssens, M.D., Nyla A. Heerema, Ph.D., Stephan Stilgenbauer, M.D., John C. Byrd, MD, Michael R. Grever, M.D.
Journal: Blood
Blood (2010) 116 (21): 58.
https://doi.org/10.1182/blood.V116.21.58.58
Published: 2010
Journal Articles

MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia.

Shuangli Mi, PhD, Jun Lu, Ph.D., Miao Sun, M.S., Zejuan Li, Ph.D., Hao Zhang, M.S., Mary Beth Neilly, M.S., Yungui Wang, Ph.D., Zhijian Qian, Ph.D., Jie Jin, M.D., Yanming Zhang, M.D., Stefan K. Bohlander, M.D., Michelle M. Le, B.A., Richard Larson, M.D., Todd R. Golub, M.D., Janet D. Rowley, M.D., Jianjun Chen, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 231.
https://doi.org/10.1182/blood.V110.11.231.231
Published: 2007